螺环酮联合帕罗西汀治疗焦虑症的疗效及安全性分析

目的:研究螺环酮联合帕罗西汀治疗焦虑症的疗效及其安全性。方法:选取2009年1月至2013年8月我院收治的符合诊断标准的焦虑症患者244例,按照知情同意原则随机分为治疗组(122例)和对照组(122例),治疗组给予丁螺环酮联合帕罗西汀治疗,对照组仅给予螺环酮治疗。治疗10周后,运用汉密尔顿焦虑量表(HAMA)及Montgomery-Asberg抑郁量表(MADS)评价疗效,运用治疗过程中不良反应症状量表(TESS)评价其安全性,比较两组患者的疗效及安全性。结果:治疗后两组的HAMA及MADS评分均低于治疗前,且治疗组低于对照组,差异均有统计学意义(P0.05);两组TEES评分在治疗第2、4、6、8、10周末均无统计学差异(P0.05)。结论:螺环酮联合帕罗西汀在治疗焦虑症时可提高疗效,且安全性高,可考虑在临床推广。

The Analysis of The Effect and Security of Buspirone Combined with Paroxetine in Treating Anxiety

Objective:To study the effect and security of buspirone combined paroxetine in the treatment of anxiety.Methods:244 patients who were diagnosed with anxiety were chosen from 2009 January to 2013 Augst in our hospital, and were divided into treatment group (122 cases) and control group (122cases) randomly according to the principle of informed and consent, treatment group was treated with buspirone combined paroxetine, while the control group was treated with buspirone alone. after 10 weeks of treatment, Hamilton anxiety scale (HAMA) and Montgomery -Asberg depression scale (MADS) were used to evaluate the effect and treatment emergent symptom scale (TESS) was used to evaluate the security, the effect and security between two groups of patients was compared.Results:The score of HAMA and MADS of two groups after treatment were all lower than those before the treatment, and the scores of the treatment group were lower than the control group, the differences were all statistically significant(P<0.05). There were no statistically differences in the comparison of the scores of TEES between two groups in the 2, 4, 6, 8, 10 weeks of treatment (P>0.05).Conclusion:Buspirone combined paroxetine can improve the effect in treating anxiety and have high security, which could be considered to be widely applied in clinic.